AIM Vaccine Co., Ltd. (HKG:6660)

Market Cap	3.61B -44.2%
Revenue (ttm)	1.38B +6.6%
Net Income	-294.87M
EPS	-0.25
Shares Out	1.23B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	97,400
Average Volume	505,960
Open	2.980
Previous Close	2.970
Day's Range	2.940 - 3.000
52-Week Range	2.890 - 6.010
Beta	0.09
RSI	34.07
Earnings Date	Mar 27, 2026

About AIM Vaccine

AIM Vaccine Co., Ltd. engages in the research and development, manufacture, and sale of vaccine products for human use in the People’s Republic of China. The company’s product pipeline includes tetravalent meningococcal conjugate vaccine, which is in phase IV clinical trial for meningococcal disease 13-Valent pneumonia conjugate and 23-valent pneumonia polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine that is in phase III clinical trial to treat COVID-19 infecti...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 1,493
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6660

Financial Performance

In 2024, AIM Vaccine's revenue was 1.29 billion, an increase of 8.22% compared to the previous year's 1.19 billion. Losses were -277.23 million, -78.69% less than in 2023.

Financial numbers in CNY